ESR1 and neoplasm: Analysis of breast tumours using phospho-specific growth factor receptor antibodies revealed that erbB-2/Her-2 overexpressing tumours are ER/PR-negative [141], indicating that increased Her-2 receptor is associated with the ER-negative phenotype.